Novo Nordisk on Feb. 2 rejected allegations by a U.S. congressional investigative committee that the company has engaged in maneuvers to increase net prices on life-saving insulin in tandem with its competitors on the U.S. insulin market.


The U.S. House Oversight Committee decided to subpoena AbbVie Inc. to seek documents on the drugmaker’s blockbuster treatments, Humira and Imbruvica, as part of an investigation into drug pricing practices.

Congressional Democrats threatened to subpoena Juul Labs if the e-cigarette maker does not provide documents relating to the company’s products and marketing practices, as a House panel looks into whether Juul deliberately targeted children.